Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226
Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. A wide variety of prenatal screening and diagnostic tests are available; each offers varying levels of information and performance, a...
Gespeichert in:
| Veröffentlicht in: | Obstetrics and gynecology (New York. 1953) Jg. 136; H. 4; S. e48 |
|---|---|
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.10.2020
|
| Schlagworte: | |
| ISSN: | 1873-233X, 1873-233X |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. A wide variety of prenatal screening and diagnostic tests are available; each offers varying levels of information and performance, and each has relative advantages and limitations. When considering screening test characteristics, no one test is superior in all circumstances, which results in the need for nuanced, patient-centered counseling from the obstetric care professional and complex decision making by the patient. Each patient should be counseled in each pregnancy about options for testing for fetal chromosomal abnormalities. It is important that obstetric care professionals be prepared to discuss not only the risk of fetal chromosomal abnormalities but also the relative benefits and limitations of the available screening and diagnostic tests. Testing for chromosomal abnormalities should be an informed patient choice based on provision of adequate and accurate information, the patient's clinical context, accessible health care resources, values, interests, and goals. All patients should be offered both screening and diagnostic tests, and all patients have the right to accept or decline testing after counseling.The purpose of this Practice Bulletin is to provide current information regarding the available screening test options available for fetal chromosomal abnormalities and to review their benefits, performance characteristics, and limitations. For information regarding prenatal diagnostic testing for genetic disorders, refer to Practice Bulletin No. 162, Prenatal Diagnostic Testing for Genetic Disorders. For additional information regarding counseling about genetic testing and communicating test results, refer to Committee Opinion No. 693, Counseling About Genetic Testing and Communication of Genetic Test Results. For information regarding carrier screening for genetic conditions, refer to Committee Opinion No. 690, Carrier Screening in the Age of Genomic Medicine and Committee Opinion No. 691, Carrier Screening for Genetic Conditions. This Practice Bulletin has been revised to further clarify methods of screening for fetal chromosomal abnormalities, including expanded information regarding the use of cell-free DNA in all patients regardless of maternal age or baseline risk, and to add guidance related to patient counseling. |
|---|---|
| AbstractList | Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. A wide variety of prenatal screening and diagnostic tests are available; each offers varying levels of information and performance, and each has relative advantages and limitations. When considering screening test characteristics, no one test is superior in all circumstances, which results in the need for nuanced, patient-centered counseling from the obstetric care professional and complex decision making by the patient. Each patient should be counseled in each pregnancy about options for testing for fetal chromosomal abnormalities. It is important that obstetric care professionals be prepared to discuss not only the risk of fetal chromosomal abnormalities but also the relative benefits and limitations of the available screening and diagnostic tests. Testing for chromosomal abnormalities should be an informed patient choice based on provision of adequate and accurate information, the patient's clinical context, accessible health care resources, values, interests, and goals. All patients should be offered both screening and diagnostic tests, and all patients have the right to accept or decline testing after counseling.The purpose of this Practice Bulletin is to provide current information regarding the available screening test options available for fetal chromosomal abnormalities and to review their benefits, performance characteristics, and limitations. For information regarding prenatal diagnostic testing for genetic disorders, refer to Practice Bulletin No. 162, Prenatal Diagnostic Testing for Genetic Disorders. For additional information regarding counseling about genetic testing and communicating test results, refer to Committee Opinion No. 693, Counseling About Genetic Testing and Communication of Genetic Test Results. For information regarding carrier screening for genetic conditions, refer to Committee Opinion No. 690, Carrier Screening in the Age of Genomic Medicine and Committee Opinion No. 691, Carrier Screening for Genetic Conditions. This Practice Bulletin has been revised to further clarify methods of screening for fetal chromosomal abnormalities, including expanded information regarding the use of cell-free DNA in all patients regardless of maternal age or baseline risk, and to add guidance related to patient counseling.Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. A wide variety of prenatal screening and diagnostic tests are available; each offers varying levels of information and performance, and each has relative advantages and limitations. When considering screening test characteristics, no one test is superior in all circumstances, which results in the need for nuanced, patient-centered counseling from the obstetric care professional and complex decision making by the patient. Each patient should be counseled in each pregnancy about options for testing for fetal chromosomal abnormalities. It is important that obstetric care professionals be prepared to discuss not only the risk of fetal chromosomal abnormalities but also the relative benefits and limitations of the available screening and diagnostic tests. Testing for chromosomal abnormalities should be an informed patient choice based on provision of adequate and accurate information, the patient's clinical context, accessible health care resources, values, interests, and goals. All patients should be offered both screening and diagnostic tests, and all patients have the right to accept or decline testing after counseling.The purpose of this Practice Bulletin is to provide current information regarding the available screening test options available for fetal chromosomal abnormalities and to review their benefits, performance characteristics, and limitations. For information regarding prenatal diagnostic testing for genetic disorders, refer to Practice Bulletin No. 162, Prenatal Diagnostic Testing for Genetic Disorders. For additional information regarding counseling about genetic testing and communicating test results, refer to Committee Opinion No. 693, Counseling About Genetic Testing and Communication of Genetic Test Results. For information regarding carrier screening for genetic conditions, refer to Committee Opinion No. 690, Carrier Screening in the Age of Genomic Medicine and Committee Opinion No. 691, Carrier Screening for Genetic Conditions. This Practice Bulletin has been revised to further clarify methods of screening for fetal chromosomal abnormalities, including expanded information regarding the use of cell-free DNA in all patients regardless of maternal age or baseline risk, and to add guidance related to patient counseling. Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. A wide variety of prenatal screening and diagnostic tests are available; each offers varying levels of information and performance, and each has relative advantages and limitations. When considering screening test characteristics, no one test is superior in all circumstances, which results in the need for nuanced, patient-centered counseling from the obstetric care professional and complex decision making by the patient. Each patient should be counseled in each pregnancy about options for testing for fetal chromosomal abnormalities. It is important that obstetric care professionals be prepared to discuss not only the risk of fetal chromosomal abnormalities but also the relative benefits and limitations of the available screening and diagnostic tests. Testing for chromosomal abnormalities should be an informed patient choice based on provision of adequate and accurate information, the patient's clinical context, accessible health care resources, values, interests, and goals. All patients should be offered both screening and diagnostic tests, and all patients have the right to accept or decline testing after counseling.The purpose of this Practice Bulletin is to provide current information regarding the available screening test options available for fetal chromosomal abnormalities and to review their benefits, performance characteristics, and limitations. For information regarding prenatal diagnostic testing for genetic disorders, refer to Practice Bulletin No. 162, Prenatal Diagnostic Testing for Genetic Disorders. For additional information regarding counseling about genetic testing and communicating test results, refer to Committee Opinion No. 693, Counseling About Genetic Testing and Communication of Genetic Test Results. For information regarding carrier screening for genetic conditions, refer to Committee Opinion No. 690, Carrier Screening in the Age of Genomic Medicine and Committee Opinion No. 691, Carrier Screening for Genetic Conditions. This Practice Bulletin has been revised to further clarify methods of screening for fetal chromosomal abnormalities, including expanded information regarding the use of cell-free DNA in all patients regardless of maternal age or baseline risk, and to add guidance related to patient counseling. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32804883$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LxDAURYOMOB_6D0SydGHH5KVtUne1OKMwOIoK7krSvmqlbcakXfjvLTjC3M09i8Nd3DmZdLZDQs45W3KWyOt0u16yg4RMhUdkxpUUAQjxPjngKZl7_zVKPE7ECZkKUCxUSszI80vhELu6-6CVdXSFvW5o9ulsa71tR05NZ90IdV-jv6Fptl3TJ6eLvi6Q3g5Ng33dXdHHoTXoKEB8So4r3Xg82_eCvK3uXrP7YLNdP2TpJigEj8MgQpBVHFcJJJpXkayM0oxDElURGMNBqYSXUoIRSQlxWUgjoUSBLNKsDBnAglz-7e6c_R7Q93lb-wKbRndoB59DKCKuYsbEqF7s1cG0WOY7V7fa_eT_N8Aviapfjg |
| CitedBy_id | crossref_primary_10_1016_j_ajog_2023_04_022 crossref_primary_10_1097_FM9_0000000000000170 crossref_primary_10_2196_38821 crossref_primary_10_1016_j_bpobgyn_2024_102543 crossref_primary_10_1007_s12687_025_00801_7 crossref_primary_10_1159_000533137 crossref_primary_10_3390_reprodmed3030017 crossref_primary_10_1097_AOG_0000000000004873 crossref_primary_10_1097_GCO_0000000000000853 crossref_primary_10_1002_uog_26177 crossref_primary_10_1080_14767058_2022_2139174 crossref_primary_10_1002_pd_6812 crossref_primary_10_1016_j_ucl_2023_04_010 crossref_primary_10_1002_pd_6139 crossref_primary_10_1097_AOG_0000000000004195 crossref_primary_10_1371_journal_pone_0312184 crossref_primary_10_3389_fgene_2024_1347942 crossref_primary_10_1016_j_ajogmf_2023_101111 crossref_primary_10_1016_j_cca_2022_08_027 crossref_primary_10_1016_j_cca_2023_117669 crossref_primary_10_1016_j_ogc_2022_07_005 crossref_primary_10_1007_s12687_023_00646_y crossref_primary_10_1186_s12884_023_06170_8 crossref_primary_10_1007_s12687_022_00604_0 crossref_primary_10_1186_s13023_022_02594_1 crossref_primary_10_3390_jpm13101468 crossref_primary_10_3389_fgene_2021_828202 crossref_primary_10_1080_14737159_2022_2125803 crossref_primary_10_1111_and_14485 crossref_primary_10_1038_s41436_021_01205_x crossref_primary_10_1002_jgc4_1703 crossref_primary_10_4103_ijnmr_ijnmr_259_21 crossref_primary_10_1016_j_rbmo_2022_03_013 crossref_primary_10_1542_peds_2022_057010 crossref_primary_10_1016_j_ajogmf_2022_100671 crossref_primary_10_1002_pd_5832 crossref_primary_10_1016_j_dhjo_2023_101514 crossref_primary_10_1016_j_jflm_2023_102491 crossref_primary_10_1002_pd_6126 crossref_primary_10_1002_pd_6247 crossref_primary_10_4103_NJCA_NJCA_119_24 crossref_primary_10_1111_jmwh_13663 crossref_primary_10_1080_14767058_2021_1907333 crossref_primary_10_1016_j_ajogmf_2021_100499 crossref_primary_10_1002_pd_5957 crossref_primary_10_1542_neo_22_11_e734 crossref_primary_10_3390_children10071233 crossref_primary_10_1016_j_jmoldx_2023_01_006 crossref_primary_10_1515_jpm_2024_0609 crossref_primary_10_1016_j_ajog_2023_04_002 crossref_primary_10_1017_erm_2024_16 crossref_primary_10_1016_j_bpobgyn_2024_102521 crossref_primary_10_1007_s10875_022_01418_y crossref_primary_10_1080_14737159_2024_2333951 crossref_primary_10_1016_j_clinbiochem_2023_110617 crossref_primary_10_1016_j_yamp_2021_07_007 crossref_primary_10_1016_j_ces_2024_120476 crossref_primary_10_2196_30404 crossref_primary_10_1146_annurev_genom_083118_015053 crossref_primary_10_1186_s12888_025_06977_z crossref_primary_10_3389_fpubh_2025_1535381 crossref_primary_10_1016_j_yamp_2021_07_002 crossref_primary_10_1002_pd_5941 crossref_primary_10_1093_clinchem_hvae170 crossref_primary_10_1016_j_gim_2024_101269 crossref_primary_10_1080_14767058_2021_1903860 crossref_primary_10_1093_jalm_jfaf062 crossref_primary_10_1186_s12884_025_07992_4 crossref_primary_10_1515_jpm_2021_0467 crossref_primary_10_1177_00045632251367280 crossref_primary_10_3389_fgene_2023_1146669 crossref_primary_10_1038_s41431_022_01248_x crossref_primary_10_1007_s00404_024_07881_9 crossref_primary_10_1097_GRF_0000000000000796 crossref_primary_10_3390_healthcare13162048 crossref_primary_10_55275_JPOSNA_2021_283 crossref_primary_10_1097_GRF_0000000000000797 crossref_primary_10_1097_GRF_0000000000000677 crossref_primary_10_1097_GRF_0000000000000798 crossref_primary_10_1007_s10815_024_03112_x crossref_primary_10_1002_pd_6111 crossref_primary_10_1097_OGX_0000000000001250 crossref_primary_10_1007_s00404_024_07514_1 crossref_primary_10_5005_jp_journals_10009_2087 crossref_primary_10_1097_AOG_0000000000005935 crossref_primary_10_1111_tog_12850 crossref_primary_10_1016_j_yamp_2025_07_001 crossref_primary_10_1097_MS9_0000000000002260 crossref_primary_10_1097_JXX_0000000000000710 crossref_primary_10_1016_j_ajog_2023_05_031 crossref_primary_10_3390_genes15070895 crossref_primary_10_1111_aogs_14091 crossref_primary_10_1097_OGX_0000000000000967 crossref_primary_10_31083_j_ceog4805161 crossref_primary_10_1080_23294515_2024_2302996 crossref_primary_10_1200_PO_25_00186 crossref_primary_10_1186_s12920_022_01280_2 crossref_primary_10_1097_AOG_0000000000004833 crossref_primary_10_1016_j_gim_2022_11_004 crossref_primary_10_1148_rg_240184 crossref_primary_10_1002_uog_29131 crossref_primary_10_1016_j_jogc_2024_102695 crossref_primary_10_1002_ijgo_14074 crossref_primary_10_1016_j_jogc_2024_102694 crossref_primary_10_1007_s00404_025_07977_w crossref_primary_10_1038_s41591_023_02774_x crossref_primary_10_1097_AOG_0000000000004395 crossref_primary_10_1055_a_2126_7476 crossref_primary_10_1097_AOG_0000000000004397 crossref_primary_10_1007_s00404_021_06203_7 crossref_primary_10_1007_s10815_024_03325_0 crossref_primary_10_1016_j_ejogrb_2024_09_014 crossref_primary_10_1007_s00261_023_03913_1 crossref_primary_10_1016_j_siny_2024_101550 crossref_primary_10_1542_peds_2024_068773 crossref_primary_10_1002_jum_16562 crossref_primary_10_1016_j_siny_2025_101613 crossref_primary_10_1126_science_adf2341 crossref_primary_10_1016_j_ajog_2024_08_017 crossref_primary_10_1515_almed_2025_0008 crossref_primary_10_1016_j_ejogrb_2023_09_023 crossref_primary_10_1097_AOG_0000000000004385 crossref_primary_10_1186_s13039_023_00642_4 crossref_primary_10_1097_AOG_0000000000004387 crossref_primary_10_1097_AOG_0000000000005594 crossref_primary_10_1097_MOP_0000000000001172 crossref_primary_10_3389_fgene_2022_906077 crossref_primary_10_1093_brain_awaf094 crossref_primary_10_3390_genes12040478 crossref_primary_10_1002_jgc4_70099 crossref_primary_10_1016_j_ajog_2023_07_055 crossref_primary_10_1097_GRF_0000000000000802 crossref_primary_10_1097_GRF_0000000000000803 crossref_primary_10_1097_GRF_0000000000000805 crossref_primary_10_18270_rsb_4825 crossref_primary_10_1097_GRF_0000000000000927 crossref_primary_10_3389_fmed_2024_1376319 crossref_primary_10_1097_AOG_0000000000005107 crossref_primary_10_1007_s10815_023_02716_z crossref_primary_10_1002_jcla_24870 crossref_primary_10_1016_j_ajog_2023_06_017 crossref_primary_10_1016_j_ajog_2023_06_018 crossref_primary_10_1111_jmwh_13674 crossref_primary_10_1016_j_infbeh_2025_102061 crossref_primary_10_1007_s40291_023_00674_x crossref_primary_10_1080_01443615_2023_2204959 crossref_primary_10_1016_j_fertnstert_2022_10_011 crossref_primary_10_1056_NEJMoa2401029 crossref_primary_10_1097_01_PGO_0000884780_20913_9c crossref_primary_10_2147_IJWH_S526271 crossref_primary_10_1097_OGX_0000000000001297 crossref_primary_10_1097_AOG_0000000000004809 crossref_primary_10_23736_S2724_606X_24_05530_1 crossref_primary_10_1002_jgc4_1682 crossref_primary_10_1542_peds_2023_065540 crossref_primary_10_1002_pd_6791 crossref_primary_10_1038_s41598_024_52767_0 crossref_primary_10_1097_AOG_0000000000005577 crossref_primary_10_1080_14767058_2023_2233662 crossref_primary_10_1097_FM9_0000000000000248 crossref_primary_10_3390_women5030030 crossref_primary_10_3389_fgene_2022_1073851 crossref_primary_10_1159_000539463 crossref_primary_10_1016_j_spen_2022_100976 crossref_primary_10_1542_neo_22_12_e805 crossref_primary_10_1136_bmjopen_2021_057658 crossref_primary_10_1007_s40291_023_00661_2 crossref_primary_10_1016_j_jsp_2022_06_002 crossref_primary_10_1016_j_rbmo_2024_103934 crossref_primary_10_1371_journal_pone_0284829 crossref_primary_10_1016_j_cll_2022_09_017 crossref_primary_10_1016_j_fertnstert_2024_07_029 crossref_primary_10_1016_j_cll_2022_09_014 crossref_primary_10_1080_10408363_2022_2162843 crossref_primary_10_1002_uog_27667 crossref_primary_10_32322_jhsm_1746967 crossref_primary_10_1371_journal_pone_0277010 crossref_primary_10_1002_jgc4_1778 crossref_primary_10_1016_j_ajog_2021_03_050 crossref_primary_10_3390_jcm14082813 crossref_primary_10_1186_s12884_023_05921_x crossref_primary_10_1016_j_ajog_2021_02_023 crossref_primary_10_1111_ajo_13533 crossref_primary_10_1002_mgg3_2479 crossref_primary_10_3390_reprodmed5020009 crossref_primary_10_1007_s44174_025_00364_8 crossref_primary_10_1002_ijgo_14834 crossref_primary_10_1002_pd_6889 crossref_primary_10_31083_j_ceog5105114 crossref_primary_10_1007_s00404_024_07500_7 crossref_primary_10_1016_j_ajog_2025_05_003 crossref_primary_10_1002_pd_6524 crossref_primary_10_1016_j_ajog_2025_05_004 crossref_primary_10_1097_FM9_0000000000000218 crossref_primary_10_1111_aogs_14351 crossref_primary_10_1016_j_ogc_2024_09_004 crossref_primary_10_1542_neo_26_2_010 crossref_primary_10_1002_uog_24818 crossref_primary_10_1002_pd_6769 crossref_primary_10_1080_14737159_2021_1919087 crossref_primary_10_1186_s12884_022_04569_3 crossref_primary_10_3389_fgene_2025_1574775 crossref_primary_10_1111_jog_15486 crossref_primary_10_1111_jog_15482 crossref_primary_10_3389_fgene_2021_661884 crossref_primary_10_1007_s10815_022_02694_8 crossref_primary_10_1002_ijgo_70305 crossref_primary_10_1080_19325037_2023_2209616 crossref_primary_10_1080_01443615_2023_2288226 crossref_primary_10_1186_s13039_024_00702_3 crossref_primary_10_3390_diagnostics13152532 crossref_primary_10_1038_s41598_023_50330_x crossref_primary_10_1016_j_ajog_2024_05_040 crossref_primary_10_1002_pd_6753 crossref_primary_10_7759_cureus_72235 crossref_primary_10_1002_jgc4_1639 crossref_primary_10_3389_fgene_2022_842092 crossref_primary_10_1210_clinem_dgaf017 crossref_primary_10_1002_puh2_70001 crossref_primary_10_1007_s00129_024_05225_x crossref_primary_10_1016_j_ogc_2023_03_005 crossref_primary_10_1111_jog_14954 crossref_primary_10_1002_pd_6191 crossref_primary_10_1038_s41598_023_30598_9 crossref_primary_10_1002_uog_26228 crossref_primary_10_1016_j_ejogrb_2025_114572 crossref_primary_10_1002_pd_6075 crossref_primary_10_1097_GRF_0000000000000957 crossref_primary_10_1002_uog_26100 crossref_primary_10_1210_jendso_bvaf007 crossref_primary_10_1002_jgc4_70107 crossref_primary_10_3389_fmed_2023_1158554 crossref_primary_10_1016_j_ssmqr_2023_100232 crossref_primary_10_1097_AOG_0000000000005891 crossref_primary_10_1002_jgc4_1649 crossref_primary_10_3389_fmed_2025_1522680 crossref_primary_10_1093_milmed_usaa375 crossref_primary_10_1097_AOG_0000000000005094 crossref_primary_10_1186_s12884_022_05139_3 crossref_primary_10_1542_neo_23_12_e829 crossref_primary_10_1002_pmf2_70016 crossref_primary_10_3390_jpm12111929 crossref_primary_10_1016_j_ajogmf_2023_101150 crossref_primary_10_1002_uog_26134 crossref_primary_10_1007_s00404_022_06900_x crossref_primary_10_1016_j_ajog_2021_11_016 crossref_primary_10_1055_s_0043_1777706 crossref_primary_10_1002_jgc4_1973 crossref_primary_10_1097_AOG_0000000000005889 crossref_primary_10_1016_j_gim_2023_100872 crossref_primary_10_1016_j_ajog_2023_03_026 crossref_primary_10_1016_j_heliyon_2024_e33437 crossref_primary_10_1016_j_gim_2023_100873 crossref_primary_10_1093_clinchem_hvaf081 crossref_primary_10_2147_IJWH_S328201 crossref_primary_10_1007_s00129_021_04834_0 crossref_primary_10_1055_a_2413_2353 crossref_primary_10_1016_j_ajog_2024_02_299 crossref_primary_10_5858_arpa_2021_0585_CP crossref_primary_10_1016_j_cca_2023_117744 crossref_primary_10_1097_01_PGO_0001024380_96363_84 crossref_primary_10_1016_j_ajog_2021_06_079 crossref_primary_10_1111_aogs_14958 crossref_primary_10_3389_ijph_2023_1605441 crossref_primary_10_1016_j_bpobgyn_2024_102575 crossref_primary_10_1111_jmwh_13745 crossref_primary_10_1016_j_bpobgyn_2024_102574 crossref_primary_10_1002_uog_27698 crossref_primary_10_1016_j_ogc_2021_06_005 crossref_primary_10_1002_pd_6298 crossref_primary_10_1080_14737159_2023_2193291 crossref_primary_10_1016_j_bpobgyn_2022_10_001 crossref_primary_10_1016_j_ajog_2022_07_022 crossref_primary_10_1080_15513815_2025_2520251 crossref_primary_10_1097_FM9_0000000000000301 crossref_primary_10_1186_s13023_024_03066_4 crossref_primary_10_1002_pd_6050 crossref_primary_10_1515_jpm_2023_0499 crossref_primary_10_1186_s13039_023_00661_1 crossref_primary_10_1002_pd_6046 crossref_primary_10_1016_j_pediatrneurol_2022_07_011 crossref_primary_10_1016_j_fertnstert_2023_08_969 crossref_primary_10_1002_pd_6849 crossref_primary_10_1016_j_gim_2022_03_019 crossref_primary_10_7759_cureus_31252 crossref_primary_10_1055_a_2312_8824 crossref_primary_10_1002_ajmg_a_62127 crossref_primary_10_1002_ajmg_c_32136 crossref_primary_10_1002_pd_6043 crossref_primary_10_1002_ajmg_a_62484 crossref_primary_10_1093_milmed_usae517 crossref_primary_10_1038_s10038_025_01332_2 crossref_primary_10_1097_AOG_0000000000005504 crossref_primary_10_1155_crpe_9504629 crossref_primary_10_1002_jgc4_1714 crossref_primary_10_1002_jgc4_70018 crossref_primary_10_1002_pd_6710 crossref_primary_10_3390_genes12030398 crossref_primary_10_1002_ijgo_70348 crossref_primary_10_1002_jgc4_1839 crossref_primary_10_3389_fgene_2021_682980 crossref_primary_10_1016_j_ajog_2023_03_008 crossref_primary_10_1016_j_clp_2025_02_001 crossref_primary_10_1016_j_tjog_2024_10_024 crossref_primary_10_1093_jalm_jfad087 crossref_primary_10_1016_j_gim_2022_10_014 crossref_primary_10_3389_fgene_2021_630787 crossref_primary_10_1007_s00438_022_01948_5 crossref_primary_10_1016_j_gene_2024_148667 crossref_primary_10_1016_j_pec_2024_108278 crossref_primary_10_1371_journal_pone_0291622 crossref_primary_10_7759_cureus_61654 crossref_primary_10_1542_neo_24_11_e744 crossref_primary_10_1080_15265161_2022_2040649 crossref_primary_10_1002_jgc4_1842 crossref_primary_10_1002_hast_1385 crossref_primary_10_1016_j_ajog_2024_05_010 crossref_primary_10_1002_pd_6029 crossref_primary_10_1159_000519116 crossref_primary_10_1016_j_lfs_2025_123530 crossref_primary_10_3390_reprodmed6020015 crossref_primary_10_1126_science_aaw3616 crossref_primary_10_1007_s41669_021_00261_y crossref_primary_10_2147_IJWH_S437214 |
| ContentType | Journal Article |
| CorporateAuthor | Society for Maternal-Fetal Medicine Committee on Genetics American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics |
| CorporateAuthor_xml | – name: American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics – name: Society for Maternal-Fetal Medicine – name: Committee on Genetics |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/AOG.0000000000004084 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-233X |
| ExternalDocumentID | 32804883 |
| Genre | Journal Article Practice Guideline |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- --K .3C .55 .GJ .XZ .Z2 01R 0R~ 123 1B1 1CY 1J1 1~5 29N 2CO 354 3O- 4.4 40H 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 77Y 7O~ 85S AAAAV AAAXR AAEDT AAGIX AAHPQ AAIQE AAJCS AALRI AAMOA AAMTA AAQFI AAQKA AAQQT AAQXK AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO AAXUO AAYWO ABASU ABBUW ABDIG ABDPE ABJNI ABMAC ABPXF ABVCZ ABWVN ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACIUM ACLDA ACOAL ACRPL ACVFH ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADCNI ADFPA ADGGA ADHPY ADMUD ADNKB ADNMO AE3 AEBDS AEETU AENEX AEUPX AFBFQ AFDTB AFEXH AFFNX AFMBP AFNMH AFPUW AFSOK AFTJW AFUWQ AGINI AGNAY AGQPQ AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKRWK AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BAWUL BOYCO BQLVK BS7 BYPQX C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FD6 FDB FEDTE FGOYB FL- FW0 GNXGY GQDEL H0~ HLJTE HVGLF HZ~ IHE IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI L-C L7B M18 M41 MZP N4W N9A NEJ NPM NQ- N~7 N~B N~M O9- OAG OAH OBH OCUKA ODA ODMTH OHH OHT OHYEH OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWX OWY OWZ OXXIT P-K P2P R2- R58 RIG RLZ ROL RPZ S4R S4S SSZ TEORI TSPGW TWZ UHB V2I VVN W3M WH7 WOQ WOW X3V X3W X7M XPP XXN XYM YQJ ZB8 ZGI ZXP ZZMQN ~S- 7X8 ADKSD ADSXY |
| ID | FETCH-LOGICAL-c3164-5e27f66f929a1f57fb8a01295f52bb128891d772b39d26dc7b72de3e05a0d4022 |
| IEDL.DBID | 7X8 |
| ISSN | 1873-233X |
| IngestDate | Wed Oct 01 15:01:01 EDT 2025 Mon Jul 21 05:32:12 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3164-5e27f66f929a1f57fb8a01295f52bb128891d772b39d26dc7b72de3e05a0d4022 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Instructional Material/Guideline-3 content type line 23 |
| PMID | 32804883 |
| PQID | 2435186003 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2435186003 pubmed_primary_32804883 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-Oct 20201001 |
| PublicationDateYYYYMMDD | 2020-10-01 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-Oct |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Obstetrics and gynecology (New York. 1953) |
| PublicationTitleAlternate | Obstet Gynecol |
| PublicationYear | 2020 |
| SSID | ssj0001693 |
| Score | 2.6912308 |
| Snippet | Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e48 |
| SubjectTerms | Chromosome Aberrations Chromosome Disorders - diagnosis Chromosome Disorders - genetics Counseling - methods Counseling - standards Counseling - supply & distribution Female Fetal Diseases - diagnosis Fetal Diseases - genetics Genetic Testing - methods Health Services Accessibility - standards Humans Patient-Centered Care - methods Patient-Centered Care - standards Pregnancy Prenatal Diagnosis - methods United States |
| Title | Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32804883 https://www.proquest.com/docview/2435186003 |
| Volume | 136 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA_qRHzx-2N-EcFHw7akaRJfZAw3H1w3UaFvo2kTEFw7rfr3e2lT9iQI9qFvgXJc736_u8vvELpyXqOYlSRNTZcERgREB2lAEq6DhAfUyFrE9UFEkYxjNfUFt9KPVTYxsQrUWZG6GnmHQl7vSUjP7HbxTtzWKNdd9Ss0VlGLAZRxI10iXqqFO6ERR7ikYIQyFjdX55To9CejWrrQP0Glb_obyKySzXD7v5-5g7Y8zMT92i920YrJ99DG2DfS99HjU-oGbiBvYUCteGgAg2MnlDsvymLuTurcodm3SnD1BvcHkxGe-htVuNHsvsZRtVAEA7o6QC_Du-fBPfHbFUjKgCMRbqiwYWgBHyU9y4XVMnFVKW451RrSllS9DLC3ZiqjYZYKLWhmmOnypJsB66SHaC0vcnOMcKhVFjJrFVg2kEoobYDaSSsU5xoIWRtdNsaagfe6lkSSm-KrnC3N1UZHtcVni1pmY8aodOGFnfzh9CnapI4IV1N2Z6hl4d8152g9_f58LT8uKreAdzQd_wA-iL2V |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Screening+for+Fetal+Chromosomal+Abnormalities%3A+ACOG+Practice+Bulletin%2C+Number+226&rft.jtitle=Obstetrics+and+gynecology+%28New+York.+1953%29&rft.date=2020-10-01&rft.issn=1873-233X&rft.eissn=1873-233X&rft.volume=136&rft.issue=4&rft.spage=e48&rft_id=info:doi/10.1097%2FAOG.0000000000004084&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-233X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-233X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-233X&client=summon |